Zr-BI 764532

Phase 1Small molecule

Zr-BI 764532 is one of 5 small molecule programs targeting Small Cell Lung Carcinoma (SCLC). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung Carcinoma (SCLC)Recruiting

Small Cell Lung Carcinoma (SCLC)Phase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Small Cell Lung Carcinoma (SCLC)

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 1

1 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 3

Ezabenlimab

Boehringer Ingelheim

Phase 1

1 4

Obrixtamig

Boehringer Ingelheim

Phase 1

1 5

Zr-BI 764532

Boehringer Ingelheim

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Small Cell Lung Carcinoma (SCLC)

NCT05963867

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03780725·8 enrolled

Small Cell Lung Carcinoma (SCLC)1 trial

An Open-label Phase 1 PET Imaging Trial to Investigate [89Zr]Zr-BI 764532 Biodistribution and Tumour Uptake in Patients With Small-cell Lung Carcinoma or Neuroendocrine Carcinoma

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05963867·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Zr-BI 764532. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zr-BI 764532 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zr-BI 764532. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Boehringer Ingelheim

Zr-BI 764532

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Small Cell Lung Carcinoma (SCLC)1 trial

References

Drug Info

Quick Facts

Related News